학술논문
The fentanyl-specific antibody FenAb024 can shield against carfentanil effects.
Document Type
Academic Journal
Author
Urban K; Panosome GmbH, Heidelberg 69123, Germany.; Gkeka A; Panosome GmbH, Heidelberg 69123, Germany.; Chandra M; Panosome GmbH, Heidelberg 69123, Germany.; Greiner D; Panosome GmbH, Heidelberg 69123, Germany.; Pollich S; Panosome GmbH, Heidelberg 69123, Germany.; Ruf S; Panosome GmbH, Heidelberg 69123, Germany; Division of Immune Diversity, German Cancer Research Center, Heidelberg 69120, Germany.; Kelemen Y; Hepione Therapeutics, Inc., New York, NY 10014, USA.; Sundermann T; Department of Forensic Toxicology, Institute for Forensic Medicine and Traffic Medicine, Heidelberg University Clinic, Heidelberg 69115, Germany.; Pravetoni M; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Department of Psychiatry and Behavioral Sciences, Department of Pharmacology, University of Washington School of Medicine, Center for Medication Development for Substance Use Disorders, Seattle, WA 98195, USA.; Baehr C; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.; Stebbins CE; Division of Structural Biology of Infection and Immunity, German Cancer Research Center, Heidelberg 69120, Germany.; Papavasiliou FN; Division of Immune Diversity, German Cancer Research Center, Heidelberg 69120, Germany.; Verdi JP; Panosome GmbH, Heidelberg 69123, Germany; Division of Immune Diversity, German Cancer Research Center, Heidelberg 69120, Germany; Hepione Therapeutics, Inc., New York, NY 10014, USA. Electronic address: j.verdi@dkfz-heidelberg.de.
Source
Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7709027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3169 (Electronic) Linking ISSN: 03784274 NLM ISO Abbreviation: Toxicol Lett Subsets: MEDLINE
Subject
Language
English
Abstract
The surge in opioid-related deaths, driven predominantly by fentanyl and its synthetic derivatives, has become a critical public health concern, which is particularly evident in the United States. While the situation is less severe in Europe, the European Monitoring Centre for Drugs and Drug Addiction reports a rise in drug overdose deaths, with emerging concerns about the impact of fentanyl-related molecules. Synthetic opioids, initially designed for medical use, have infiltrated illicit markets due to their low production costs and high potency, with carfentanil posing additional threats, including potential chemical weaponization. Existing overdose mitigation heavily relies on naloxone, requiring timely intervention and caregiver presence, while therapeutic prevention strategies face many access challenges. To provide an additional treatment option, we propose the use of a fentanyl-specific monoclonal antibody (mAb), as a non-opioid method of prophylaxis against fentanyl and carfentanil. This mAb shows protection from opioid effects in a pre-clinical murine model. mAbs could emerge as a versatile countermeasure in civilian and biodefense settings, offering a novel approach to combat opioid-associated mortality.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Joseph Verdi reports financial support was provided by National Institute on Drug Abuse. Nina Papavasiliou reports financial support was provided by Helmholtz Foundation. Erec Stebbins reports financial support was provided by Helmholtz Foundation. Joseph Verdi reports a relationship with Hepione Therapeutics Inc. that includes: employment and equity or stocks. Nina Papavasiliou reports a relationship with Hepione Therapeutics Inc. that includes: equity or stocks. Erec Stebbins reports a relationship with Hepione Therapeutics Inc. that includes: board membership and equity or stocks. Yosip Kelemen reports a relationship with Hepione Therapeutics Inc. that includes: employment. Joseph Verdi reports a relationship with Panosome GmbH that includes: employment and equity or stocks. Nina Papavasiliou reports a relationship with Panosome GmbH that includes: board membership and equity or stocks. Erec Stebbins reports a relationship with Panosome GmbH that includes: board membership and equity or stocks. Anastasia Gkeka reports a relationship with Panosome GmbH that includes: employment and equity or stocks. Katharina Urban reports a relationship with Panosome GmbH that includes: employment and equity or stocks. Monica Chandra reports a relationship with Panosome GmbH that includes: employment and equity or stocks. Dennis Greiner reports a relationship with Panosome GmbH that includes: employment. Sandra Ruf reports a relationship with Panosome GmbH that includes: equity or stocks. Selina Pollich reports a relationship with Panosome GmbH that includes: employment. Joseph Verdi has patent pending to Hepione Therapeutics Inc. Nina Papavasiliou has patent pending to Hepione Therapeutics Inc. Erec Stebbins has patent pending to Hepione Therapeutics Inc. Yosip Kelemen has patent pending to Hepione Therapeutics Inc. Marco Pravetoni has patent pending to University of Minnesota. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Joseph Verdi reports financial support was provided by National Institute on Drug Abuse. Nina Papavasiliou reports financial support was provided by Helmholtz Foundation. Erec Stebbins reports financial support was provided by Helmholtz Foundation. Joseph Verdi reports a relationship with Hepione Therapeutics Inc. that includes: employment and equity or stocks. Nina Papavasiliou reports a relationship with Hepione Therapeutics Inc. that includes: equity or stocks. Erec Stebbins reports a relationship with Hepione Therapeutics Inc. that includes: board membership and equity or stocks. Yosip Kelemen reports a relationship with Hepione Therapeutics Inc. that includes: employment. Joseph Verdi reports a relationship with Panosome GmbH that includes: employment and equity or stocks. Nina Papavasiliou reports a relationship with Panosome GmbH that includes: board membership and equity or stocks. Erec Stebbins reports a relationship with Panosome GmbH that includes: board membership and equity or stocks. Anastasia Gkeka reports a relationship with Panosome GmbH that includes: employment and equity or stocks. Katharina Urban reports a relationship with Panosome GmbH that includes: employment and equity or stocks. Monica Chandra reports a relationship with Panosome GmbH that includes: employment and equity or stocks. Dennis Greiner reports a relationship with Panosome GmbH that includes: employment. Sandra Ruf reports a relationship with Panosome GmbH that includes: equity or stocks. Selina Pollich reports a relationship with Panosome GmbH that includes: employment. Joseph Verdi has patent pending to Hepione Therapeutics Inc. Nina Papavasiliou has patent pending to Hepione Therapeutics Inc. Erec Stebbins has patent pending to Hepione Therapeutics Inc. Yosip Kelemen has patent pending to Hepione Therapeutics Inc. Marco Pravetoni has patent pending to University of Minnesota. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)